Adeshwar Meditex Ltd

Adeshwar Meditex reported a net profit of 0.79 crore and net sales of 64.76 crore for the year ending March 2022, with an operating profit margin of 5.2%. Total liabilities and assets were both 72.45 crore, and the book value per share increased to 21.45.

The next results date for Adeshwar Meditex is 12 November 2025.

As of November 7, 2025, Adeshwar Meditex is fairly valued with a PE ratio of 12.77 and an EV to EBITDA of 8.25, making it more attractively priced than peers like Poly Medicure and Vimta Labs, despite a year-to-date stock performance decline of -26.04%.

As of November 7, 2025, Adeshwar Meditex is fairly valued with a PE ratio of 12.77 and an EV to EBITDA of 8.25, significantly lower than peers like Poly Medicure and Blue Jet Health, and while it has underperformed the Sensex long-term, it recently achieved a positive return of 3.95%.

As of November 7, 2025, Adeshwar Meditex is fairly valued with a PE ratio of 12.77, but has underperformed the Sensex with a stock return of -18.38% over the past year, suggesting potential for future growth.

As of November 6, 2025, Adeshwar Meditex is considered overvalued with a PE ratio of 13.41, an EV to EBITDA of 8.56, and a PEG ratio of 4.49, especially given its -26.04% year-to-date return compared to the Sensex's 6.62% gain.

As of October 30, 2025, Adeshwar Meditex is fairly valued with a PE ratio of 12.90, significantly lower than its expensive peers, and has outperformed the Sensex with a 7.25% return over the past month.

As of October 29, 2025, Adeshwar Meditex is considered overvalued with a PE ratio of 14.15 and has underperformed the Sensex with a year-to-date return of -21.92%, although it is more attractively priced compared to peers like Poly Medicure and Vimta Labs.

As of October 20, 2025, Adeshwar Meditex is fairly valued with a PE Ratio of 12.55 and an EV to EBITDA of 8.15, significantly lower than peers like Poly Medicure and Blue Jet Health, despite underperforming the Sensex with a return of -18.18%.

As of October 14, 2025, Adeshwar Meditex is considered overvalued with a PE ratio of 15.20 and a high PEG ratio of 5.09, despite a recent 34.57% short-term gain, contrasting with a year-to-date decline of 16.15% and higher valuations compared to peers like Raaj Medisafe and BPL.

As of October 13, 2025, Adeshwar Meditex is fairly valued with a PE ratio of 13.33 and an EV to EBITDA of 8.52, especially when compared to higher-valued peers like Poly Medicure and Blue Jet Health, despite underperforming the Sensex over the past year.

As of October 1, 2025, Adeshwar Meditex is considered undervalued with a PE ratio of 11.29 and an attractive valuation grade, indicating strong growth potential despite a recent underperformance compared to the Sensex.

As of October 1, 2025, Adeshwar Meditex is considered undervalued with attractive valuation metrics, including a PE ratio of 11.29 and an EV to EBITDA of 7.56, especially compared to peers like Poly Medicure and Blue Jet Health, despite a year-to-date stock performance trailing the Sensex.

As of September 23, 2025, Adeshwar Meditex is fairly valued with a PE ratio of 13.59, an EV to EBITDA of 8.64, and a Price to Book Value of 0.76, indicating a shift from attractive to fair valuation compared to peers like Poly Medicure and Blue Jet Health, despite recent stock performance showing mixed results against the Sensex.

As of August 29, 2025, Adeshwar Meditex is considered undervalued with a PE ratio of 12.79 and an attractive valuation grade, especially compared to peers like Poly Medicure and Blue Jet Health, despite a year-to-date return of -29.46%.

As of August 29, 2025, Adeshwar Meditex is considered an attractive investment due to its undervalued financial metrics, including a PE ratio of 12.79 and a Price to Book Value of 0.76, especially when compared to higher valuations of peers like Poly Medicure and Blue Jet Health.

As of August 29, 2025, Adeshwar Meditex is considered undervalued with a PE ratio of 12.79 and has shifted from fair to attractive valuation, outperforming the Sensex and trading at a discount compared to peers like Poly Medicure and Blue Jet Health.

As of August 25, 2025, Adeshwar Meditex is fairly valued with a PE ratio of 13.53, an EV to EBITDA of 9.32, and a ROCE of 8.12%, but has underperformed the Sensex with a 17.83% decline over the past year compared to a 0.68% gain in the index.

As of August 22, 2025, Adeshwar Meditex is considered undervalued with attractive financial ratios, such as a PE of 12.20 and an EV to EBITDA of 8.69, especially when compared to its expensive peers, suggesting potential for recovery despite recent underperformance.